Latest news with #Sjögren'ssyndrome
Yahoo
08-05-2025
- Business
- Yahoo
Exagen Inc. Prices Public Offering of Common Stock
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share. All of the shares in the offering will be sold by Exagen, with gross proceeds to Exagen expected to be $17,587,500 before deducting underwriting discounts and commissions and offering expenses. Exagen has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares on the same terms and conditions. The offering is expected to close on May 9, 2025, subject to the satisfaction of customary closing conditions. Canaccord Genuity is acting as sole bookrunner for the offering. The public offering is being made pursuant to a shelf registration statement on Form S-3 (including a base prospectus) that was previously filed with the Securities and Exchange Commission (the 'SEC') on November 17, 2023, as amended on November 27, 2023, and declared effective by the SEC on November 29, 2023. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website located at Copies of the final prospectus supplement and the accompanying prospectus relating to this offering, when available, can be obtained from Canaccord Genuity LLC, Attention: Syndication Department, 1 Post Office Square, Suite 3000, Boston, MA 02109, or by email at prospectus@ This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Exagen Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen's mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The Company's flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren's syndrome earlier and with greater accuracy. Exagen's laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE®-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, please visit or follow @ExagenInc on X. Forward-Looking Statements Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the completion of the public offering and other risks and uncertainties that are described under the heading 'Risk Factors' in Exagen's preliminary prospectus filed with the SEC on May 7, 2025, Exagen's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 11, 2025 and any subsequent filings with the SEC. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact:Ryan DouglasExagen in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
30-04-2025
- Health
- Time of India
Pulmonary Fibrosis: An Underdiagnosed and Progressive Lung Disease
What is Pulmonary Fibrosis? Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterised by excessive fibrotic tissue deposition in the pulmonary parenchyma. The term "pulmonary" refers to the lungs, while "fibrosis" denotes pathological scarring. The disease disrupts normal alveolar architecture, leading to impaired gas exchange, reduced lung compliance, and progressive respiratory insufficiency. PF encompasses over 200 ILDs, with idiopathic pulmonary fibrosis (IPF) being the most common and severe form. Histopathologically, PF features chronic inflammation, fibroblast proliferation, and excessive extracellular matrix deposition, predominantly collagen. Unlike inflammatory ILDs, IPF follows an irreversible fibrotic course, leading to a steady decline in lung function. Global and Regional Prevalence of Pulmonary Fibrosis Pulmonary fibrosis is a growing global health concern with varying epidemiological trends. In Western populations, IPF prevalence ranges from 2 to 29 cases per 100,000 individuals, with incidence increasing due to aging populations and improved diagnostic capabilities. The disease predominantly affects males aged 50 to 70 years. In India, PF remains underrecognized, especially in primary care settings. While tertiary centres frequently diagnose PF, awareness among general practitioners is inadequate. Studies suggest that IPF accounts for 29-48 per cent of diffuse parenchymal lung disease (DPLD) cases in Indian hospitals. Factors such as air pollution, occupational exposures, biomass fuel inhalation, and smoking suggest that PF cases may be significantly underestimated. Risk Factors and Etiology of Pulmonary Fibrosis PF etiology is multifactorial, involving both intrinsic and extrinsic contributors: Environmental and Occupational Exposure: Chronic inhalation of inorganic and organic particulates, such as silica, asbestos, and coal dust, can induce lung fibrosis. Hypersensitivity pneumonitis from organic dusts like bird droppings and mold spores can also lead to Causes: Radiation therapy, cytotoxic drugs (e.g., bleomycin, methotrexate, amiodarone), and certain antibiotics are associated with lung Use: Smoking accelerates disease progression and worsens clinical Diseases: Systemic disorders such as rheumatoid arthritis, systemic sclerosis, and Sjögren's syndrome are strongly associated with pulmonary Susceptibility: Mutations in genes encoding surfactant proteins (SFTPC, SFTPA2), telomerase components (TERT, TERC), and mucin-producing proteins (MUC5B) have been linked to familial pulmonary Reflux Disease (GERD): Chronic micro aspiration of gastric contents contributes to persistent alveolar injury and fibrotic remodelling. Clinical Presentation of Pulmonary Fibrosis Early recognition of PF is crucial for timely intervention. Common clinical manifestations include: Progressive exertional dyspneaPersistent dry, non-productive coughFatigue and generalized myalgiaUnexplained weight loss and anorexiaDigital clubbing due to chronic hypoxiaBibasilar inspiratory "Velcro crackles" on auscultation Untreated PF can lead to complications such as pulmonary hypertension, right ventricular dysfunction (cor pulmonale), acute exacerbations, and an increased risk of lung malignancies. Diagnostic Approach to Pulmonary Fibrosis PF is often misdiagnosed as chronic obstructive pulmonary disease (COPD), asthma, or pneumonia. A multimodal diagnostic approach is essential: 1. Clinical Assessment: Detailed history, symptomatology, and occupational/environmental exposure evaluation. 2. Pulmonary Function Tests (PFTs): Restrictive ventilatory defect (reduced forced vital capacity [FVC] with preserved FEV1/FVC ratio).Decreased diffusion capacity of the lungs for carbon monoxide (DLCO). 3. Imaging Studies: High-resolution computed tomography (HRCT): Identifies reticular opacities, honeycombing, and traction bronchiectasis, characteristic of PF. Tests: Autoimmune serology (ANA, RF, anti-CCP) for connective tissue disease- associated PF. Biopsy (in select cases): Surgical lung biopsy or transbronchial lung cryobiopsy may be required for definitive histopathological diagnosis. Management and Treatment Strategies Although fibrotic lung tissue is irreversible, several therapeutic options can slow disease progression and alleviate symptoms: Antifibrotic Agents-Pirfenidone: Reduces fibroblast proliferation and collagen A tyrosine kinase inhibitor that targets profibrotic pathways (VEGFR, FGFR, and PDGFR).Immunomodulators (for non-IPF PF): Corticosteroids, azathioprine, or mycophenolate mofetil in autoimmune-related Therapy: Supplemental oxygen improves exercise tolerance and reduces hypoxic Rehabilitation: Supervised exercise programs and breathing techniques enhance functional Transplantation: The only curative option for advanced-stage PF, with patient selection based on pulmonary function impairment, oxygen dependence, and overall health status. Role of Support Systems in Pulmonary Fibrosis Care Comprehensive PF management extends beyond pharmacological interventions. Multidisciplinary care teams comprising pulmonologists, physiotherapists, dietitians, and psychologists play a pivotal role. Patient advocacy groups, caregiver networks, and telemedicine programs enhance disease awareness and provide essential psychosocial support. Future Perspectives and Conclusion Historically, IPF prognosis was poor, with a median survival of 3-5 years post-diagnosis. However, emerging therapies and early intervention have improved life expectancy. Novel antifibrotic agents, regenerative medicine approaches (stem cell therapy), and gene-targeted interventions hold promise for transforming PF management. Increasing disease awareness, improving diagnostic capabilities, and expanding treatment accessibility are critical to combating pulmonary fibrosis. A multifaceted approach combining pharmacotherapy, lifestyle modifications, and robust support systems will be instrumental in improving patient outcomes and quality of life. Dr Devi "Patients with pulmonary fibrosis often present with unexplained breathlessness and chronic dry cough. Early referral to a pulmonologist can prevent delays in diagnosis and initiation of treatment." Dr Partha PratimBose , MD, DTCD, DNB, FISDA, FBPI, MBA, Senior consultant & Faculty Pulmonologist, National Heart Institute, New Delhi, Founder SAANS foundation, India, Pulmonary Fibrosis: A Post-COVID Concern "Pulmonary fibrosis is not an uncommon lung condition, and a persistent dry cough in the post-COVID era warrants thorough evaluation. Early diagnosis with HRCT chest imaging can help prevent disease progression. With advanced therapeutics and a well-structured pulmonary rehabilitation program, effective management is possible, improving both lung health and overall quality of life." Dr. Shubhranshu Subh , MBBS, MD, Consultant Pulmonologist, Jeevan Rekha hospital , Jaipur, " Pulmonary fibrosis is a progressive lung disease that leads to scarring, making breathing increasingly difficult. Symptoms like chronic cough, fatigue, and shortness of breath are often mistaken for aging or other conditions, delaying diagnosis. While there is no cure, early detection can slow progression and improve quality of life. Raising awareness is crucial—if you or a loved one experience these symptoms, seek medical advice promptly. Timely intervention saves lives." Dr. Amit Kumar Mandal ,Director, Pulmonology, Sleep and Critical Care, Fortis Hospital, Mohali,"While pulmonary fibrosis has no known cure, certain precautions can help reduce the risk. Avoid exposure to harmful pollutants, quit smoking, and prioritize lung health through regular exercise and medical check-ups. Early detection is key—if you experience persistent breathlessness or chronic cough, seek medical advice promptly. Protect your lungs today to breathe easier tomorrow. Awareness and prevention are the first steps toward a healthier future." Dr Viswesvaran Balasubramanian , MD, DM (Pulmonary Medicine and Critical care - Gold medalist), Fellowship in Interventional, Pulmonology (Malaysia) & Sleep Medicine, Senior Consultant- Interventional Pulmonology, ECMO & Lung Transplantation team, Yashoda Hospitals, Somajiguda , Hyderabad, " Fibrosis is a silent threat that can damage vital organs over time. Early detection and proactive care are key to managing its impact. Stay informed, prioritize regular check-ups, and adopt a healthy lifestyle to safeguard your well-being. Awareness today can prevent complications tomorrow." Disclaimer - The above content is non-editorial, and ET Healthworld hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
Yahoo
25-02-2025
- Business
- Yahoo
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024, before the market opens on Tuesday, March 11, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 AM ET (5:30 AM PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at A replay of the conference call will be available until Monday, April 14, 2025, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay by dialing 201-612-7415 (U.S.) or +1-877-660-6853 (international) using passcode 13751928. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes. About Exagen Inc. Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen's mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company's flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren's syndrome earlier and with greater accuracy. Exagen's laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, visit or follow @ExagenInc on X. Contact:Ryan DouglasExagen in to access your portfolio
